From suppressor to enhancer: IL-10's alternative role in CAR-T cell therapies against solid tumors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38458175.
- Also identified by DOI 10.1016/j.stem.2024.02.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Aiming to improve the effector function of CAR-T cells, Zhao et al.<sup>1</sup> report that IL-10 metabolically reprograms CAR-T cells, and this promotes their effectiveness against solid tumors and challenges IL-10's perceived role as merely immunosuppressive. This simple but promising strategy fosters durable immune memory and eagerly awaits validation in clinical trials.
Medical subject headings
- Interleukin-10
- Neoplasms